Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Дифференцированный подход при назначении нестероидных препаратов: «спринтеры» и «стайеры» анальгетической терапии
Каратеев А.Е., Зубков Д.С. Дифференцированный подход при назначении нестероидных препаратов: «спринтеры» и «стайеры» анальгетической терапии. Consilium Medicum. 2019; 21 (9): 142–148. DOI: 10.26442/20751753.2019.9.190688
________________________________________________
Karateev A.E., Zubkov D.S. Differentiated approach to prescription of non-steroid drugs: “sprinters” and “stayers” of analgesic treatment. Consilium Medicum. 2019; 21 (9): 142–148. DOI: 10.26442/20751753.2019.9.190688
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Нестероидные противовоспалительные препараты – основной инструмент для лечения скелетно-мышечной боли. Различие в фармакологических свойствах и профиле безопасности этих препаратов позволяет разделить «сценарии» их клинического использования. Для купирования острой интенсивной боли целесообразно применять неселективные нестероидные противовоспалительные препараты с высоким быстродействием и максимальным обезболивающим потенциалом. Пользуясь спортивной терминологией, их можно назвать «спринтерами» анальгетической терапии. К ним следует отнести хорошо известный российским врачам кетопрофен. Для длительного контроля скелетно-мышечной боли целесообразно применять селективные ингибиторы циклооксигеназы 2-го типа, обладающие хорошим профилем безопасности. Это «стайеры» обезболивающего лечения, ярким представителем которых следует считать эторикоксиб. В настоящем обзоре приводятся 2 клинических случая, иллюстрирующих подходы к использованию данных препаратов в реальной клинической практике.
Ключевые слова: скелетно-мышечная боль, неспецифическая боль в спине, остеоартрит, нестероидные противовоспалительные препараты, кетопрофен, эторикоксиб.
Ключевые слова: скелетно-мышечная боль, неспецифическая боль в спине, остеоартрит, нестероидные противовоспалительные препараты, кетопрофен, эторикоксиб.
________________________________________________
Non-steroid anti-inflammatory drugs are the main instrument for musculoskeletal pain treatment. Differences in pharmacologic properties and safety profile of these medications allow to divide the “scenarios” of their clinical use. For acute pain treatment it is reasonable to use non-selective non-steroid anti-inflammatory drugs with rapid response time and maximum analgesic potential. Using sport terminology we will call them “sprinters” of analgesic therapy. These medications include ketoprofen that is well known by Russian medical practitioners. For long-term treatment of musculoskeletal pain it is reasonable to use selective cyclo-oxygenase-2 inhibitors with good safety profile. These medications are the “stayers” of analgesic treatment; etoricoxib is one of the prominent representatives of the group. The review presents 2 clinical cases that illustrate approaches to the use of these medications in real clinical practice.
Key words: musculoskeletal pain, non-specific back pain, osteoarthritis, non-steroid anti-inflammatory drugs, ketoprofen, etoricoxib.
Key words: musculoskeletal pain, non-specific back pain, osteoarthritis, non-steroid anti-inflammatory drugs, ketoprofen, etoricoxib.
Полный текст
Список литературы
1. Боль. Практическое руководство для врачей. Под ред. Н.Н.Яхно, М.Л.Кукушкина. М.: Изд-во РАМН, 2012.
[Pain. Practical Guide for Doctors. Pod red. N.N.Iakhno, M.L.Kukushkina. Moscow: Izd-vo RAMN, 2012 (in Russian).]
2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic anlysis for the Global Burden of Disease Study 2017. Lancet 2018;392 (10159): 1789–858. DOI: 10.1016/S0140-6736 (18)32279-7. Epub 2018 Nov 8.
3. Allegri M, Montella S, Salici F et al. Mechanisms of low back pain: a guide for diagnosis and therapy. Version 2. F1000Res. 2016 Jun 28 [revised 2016 Oct 11]; 5; pii: F1000 Faculty Rev-1530. eCollection 2016.
4. Shmagel A, Foley R, Ibrahim H. Epidemiology of Chronic Low Back Pain in US Adults: Data From the 2009–2010 National Health and Nutrition Examination Survey. Arthritis Care Res (Hoboken) 2016; 68 (11): 1688–94. DOI: 10.1002/acr.22890
5. O'Neill TW, McCabe PS, McBeth J. Update on the epidemiology, risk factors and disease outcomes of osteoarthritis. Best Pract Res Clin Rheumatol 2018; 32 (2): 312–26. DOI: 10.1016/j.berh.2018.10.007. Epub 2018 Nov 22.
6. Vos T, Flaxman AD, Naghavi M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859): 2163e96.
7. Cisternas MG, Murphy L, Sacks JJ et al. Alternative methods for defining osteoarthritis and the impact on estimating prevalence in a US population-based survey. Arthritis Care Res 2016; 68 (5): 574e80.
8. http: //www.gks.ru/free_doc/doc_2017/zdrav17.pdf
9. Верткин А.Л., Каратеев А.Е., Кукушкин М.Л. и др. Ведение пациентов с болью в спине для терапевтов и врачей общей практики (клинические рекомендации). Терапия. 2018; 2 (20): 8–18.
[Vertkin A.L., Karateev A.E., Kukushkin M.L. et al. Vedenie patsientov s bol'iu v spine dlia terapevtov i vrachei obshchei praktiki (klinicheskie rekomendatsii). Terapiia. 2018; 2 (20): 8–18 (in Russian).]
10. Qaseem A, Wilt TJ, McLean RM et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med 2017. DOI: 10.7326/M16-2367
11. Bernstein IA, Malik Q, Carville S, Ward S. Low back pain and sciatica: summary of NICE guidance. BMJ 2017; 356: i6748. DOI: 10.1136/bmj.i6748
12. Российские клинические рекомендации. Ревматология. Под ред. Е.Л.Насонова. М.: ГЭОТАР-Медиа, 2017.
[Russian clinical recommendations. Rheumatology. Pod red. E.L.Nasonova. Moscow: GEOTAR-Media, 2017 (in Russian).]
13. Bannuru RR, Osani MC, Vaysbrot EE et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 2019; pii: S1063-4584 (19)31116-1. DOI: 10.1016/j.joca.2019.06.011
14. Bruyère O, Honvo G, Veronese N et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum 2019; pii: S0049-0172 (19)30043-5. DOI: 10.1016/j.semarthrit.2019.04.008
15. http://www.consultant.ru/cons/cgi/online.cgi?req=doc&base=EXP&n=414750# 06438418585438186
16. Chou R, Fu R, Carrino JA, Deyo RA. Imaging strategies for low-back pain: systematic review and meta-analysis. Lancet 2009; 373 (9662): 463–72. DOI: 10.1016/S0140-6736 (09)60172-0
17. Sarzi-Puttini P, Atzeni F, Lanata L et al. Pain and ketoprofen: what is its role in clinical practice? Reumatismo 2010; 62 (3): 172–88.
18. Kokki H. Ketoprofen pharmacokinetics, efficacy, and tolerability in pediatric patients. Paediatr Drugs 2010; 12 (5): 313–29.
19. Díaz-Reval M, Ventura-Martínez R, Déciga-Campos M et al. Evidence for a central mechanism of action of S- (+)-ketoprofen. Eur J Pharmacol 2004; 483 (2–3): 241–8.
20. Gaskell H, Derry S, Wiffen PJ, Moore RA. Single dose oral ketoprofen or dexketoprofen for acute postoperative pain in adults. Cochrane Database Syst Rev 2017; 5: CD007355. DOI: 10.1002/14651858.CD007355.pub3
21. Sarzi-Puttini P, Atzeni F, Lanata L, Bagnasco M. Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis. Clin Exp Rheumatol 2013; 31 (5): 731–8. Epub 2013 May 17.
22. Le Loet X. Safety of ketoprofen in the elderly: a prospective study on 20,000 patients. Scand J Rheumatol (Suppl.) 1989; 83: 21–7.
23. Helin-Salmivaara A, Saarelainen S, Gronroos J et al. Risk of upper gastrointestinal events with the use of various NSAIDs: A case-control study in a general population. Scan J Gastroenterol 2007; 42: 923–32.
24. Чичасова Н.В., Иммаметдинова Г.Р., Каратеев А.Е. и др. Эффективность и безопасность кетопрофена (кетонал) при ревматоидном артрите (клинико-эндоскопическое исследование). Научно-практическая ревматология. 2001; 1: 47–52.
[Chichasova N.V., Immametdinova G.R., Karateev A.E. et al. Effektivnost' i bezopasnost' ketoprofena (ketonal) pri revmatoidnom artrite (kliniko-endoskopicheskoe issledovanie). Nauchno-prakticheskaia revmatologiia. 2001; 1: 47–52 (in Russian).]
25. Осипова Н.А., Петрова В.В., Ермолаев П.М., Береснев В.А. Нестероидные противовоспалительные препараты в лечении послеоперационной боли у онкологических больных. Фарматека, 2006; 6 (121).
[Osipova N.A., Petrova V.V., Ermolaev P.M., Beresnev V.A. Nesteroidnye protivovospalitel'nye preparaty v lechenii posleoperatsionnoi boli u onkologicheskikh bol'nykh. Farmateka, 2006; 6 (121) (in Russian).]
26. Шмидт Е.И., Коган К.М., Белозерова И.В. Оценка эффективности кетонала ретард у больных остеоартрозом. Научно-практическая ревматология. 2000; 2: 77–9.
[Shmidt E.I., Kogan K.M., Belozerova I.V. Otsenka effektivnosti ketonala retard u bol'nykh osteoartrozom. Nauchno-prakticheskaia revmatologiia. 2000; 2: 77–9 (in Russian).]
27. Новиков Г.А., Вайсман М.А., Прохоров Б.М. и др. Кетонал в лечении болевого синдрома у пациентов с распространенными формами злокачественных новообразований. Паллиативная медицина и реабилитация. 2002; 3: 48–51.
[Novikov G.A., Vaisman M.A., Prokhorov B.M. et al. Ketonal v lechenii bolevogo sindroma u patsientov s rasprostranennymi formami zlokachestvennykh novoobrazovanii. Palliativnaia meditsina i reabilitatsiia. 2002; 3: 48–51 (in Russian).]
28. Лазебник Л.Б., Дроздов В.Н., Коломиец Е.В. Сравнительная эффективность и безопасность применения кетопрофена, лорноксикама, нимесулида и целекоксиба у больных остеоартрозом. РМЖ. 2004; 12 (14): 844–7.
[Lazebnik L.B., Drozdov V.N., Kolomiets E.V. Sravnitel'naia effektivnost' i bezopasnost' primeneniia ketoprofena, lornoksikama, nimesulida i tselekoksiba u bol'nykh osteoartrozom. RMZh. 2004; 12 (14): 844–7 (in Russian).]
29. Singh G, Mithal A., Triadafilopoulos G. Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis; selectivity is with patients, not the drug. Ann Rheum Dis 2005; 64 (Suppl. 3): 85.
30. Solomon D, Glynn R, Levin R, Avorn J. Nonsteroidal Anti-inflammatory Drug Use and Acute Myocardial Infarction. Arch Intern Med 2002; 162: 1099–104.
31. Helin-Salmivaara A, Virtanen A, Vesalainen R et al. NSAID use and the risk of hospatalisation for first myocardial infarction in the general population: a national case-control study from Finland. Eur Heart J 2006; 27: 1657–63.
32. Данилов А.Б. Кетонал ДУО в лечении болевого синдрома. Эффективная фармакотерапия. Неврология и психиатрия. 2013; 1: 8–10.
[Danilov A.B. Ketonal DUO v lechenii bolevogo sindroma. Effektivnaia farmakoterapiia. Nevrologiia i psikhiatriia. 2013; 1: 8–10 (in Russian).]
33. Филатова Е.Г. Кетонал: возможности ступенчатой терапии острой боли. Лечение заболеваний нервной системы. 2015; 2.
[Filatova E.G. Ketonal: vozmozhnosti stupenchatoi terapii ostroi boli. Lechenie zabolevanii nervnoi sistemy. 2015; 2 (in Russian).]
34. Чичасова Н.В., Камалова Р.Г., Плаксина Т.В., Попов А.А. Новые аспекты лечения хронической̆ боли: многоцентровое открытое клиническое испытание препарата Кетонал Дуо у больных с дегенеративными заболеваниями суставов. НПР. 2014; 52 (2): 195–201.
[Chichasova N.V., Kamalova R.G., Plaksina T.V., Popov A.A. Novye aspekty lecheniia khronicheskoй̆ boli: mnogotsentrovoe otkrytoe klinicheskoe ispytanie preparata Ketonal Duo u bol'nykh s degenerativnymi zabolevaniiami sustavov. NPR. 2014; 52 (2): 195–201 (in Russian).]
35. https: //www.rlsnet.ru/tn_index_id_41660.htm
36. Matsumoto A, Cavanaugh P. Etoricoxib. Drugs Today (Barc) 2004; 40 (5): 395–414.
37. Martina S, Vesta K, Ripley T. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother 2005; 39 (5): 854–62.
38. Давыдов О.С. Периферические и центральные механизмы перехода острой боли в хроническую и возможная роль ингибирования циклооксигеназы 2 в предотвращении хронизации болевого синдрома. Неврология, нейропсихиатрия, психосоматика. 2016; 8 (2): 10–6.
[Davydov O.S. Perifericheskie i tsentral'nye mekhanizmy perekhoda ostroi boli v khronicheskuiu i vozmozhnaia rol' ingibirovaniia tsiklooksigenazy 2 v predotvrashchenii khronizatsii bolevogo sindroma. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2016; 8 (2): 10–6 (in Russian).]
39. Clarke R, Derry S, Moore R. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev 2012; 4: CD004309.
40. Schumacher H, Boice J, Dahikh D et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002; 324: 1488–92.
41. Da Costa BR, Reichenbach S, Keller N et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 2016; 387 (10033): 2093–105.
42. Jung SY, Jang EJ, Nam SW et al. Comparative effectiveness of oral pharmacologic interventions for knee osteoarthritis: A network meta-analysis. Mod Rheumatol 2018; 28 (6): 1021–8. DOI: 10.1080/14397595.2018.1439694. Epub 2018 Mar 1.
43. Zacher J, Feldman D, Gerli R et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin 2003; 19 (8): 725–36.
44. Reginster J, Malmstrom K, Mehta A et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis 2007; 66 (7): 945–51.
45. Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis. Pain 2016; 157 (8): 1634–44.
46. Moss P, Benson HAE, Will R, Wright A. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage 2017; pii: S1063-4584 (17)31091-9.
47. Ramey D, Watson D, Yu C et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005; 21 (5): 715–22.
48. Watson D, Bolognese J, Yu C et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin 2004; 20 (12): 1899–908.
49. Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. PLoS One 2018; 13 (1): e0190798. DOI: 10.1371/journal.pone.0190798. eCollection 2018.
50. Cannon C, Curtis S, FitzGerald G et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368: 1771–81.
51. Каратеев А.Е. Дестабилизация артериальной гипертензии как осложнение терапии нестероидными противовоспалительными препаратами: значение проблемы. Современная ревматология. 2018; 12 (2): 64–72. https://doi.org/10.14412/1996-7012-2018-2-64-72
[Karateev A.E. Destabilizatsiia arterial'noi gipertenzii kak oslozhnenie terapii nesteroidnymi protivovospalitel'nymi preparatami: znachenie problemy. Sovremennaia revmatologiia. 2018; 12 (2): 64–72. https://doi.org/10.14412/1996-7012-2018-2-64-72 (in Russian).]
52. Клинические рекомендации Общероссийской общественной организации Ассоциация травматологов-ортопедов России «Гонартроз» КР 418, зарегистрированы 2016 г. https://medi.ru/klinicheskie-rekomendatsii/gonoartroz_13985/[Pain. Practical Guide for Doctors. Pod red. N.N.Iakhno, M.L.Kukushkina. Moscow: Izd-vo RAMN, 2012 (in Russian).]
2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic anlysis for the Global Burden of Disease Study 2017. Lancet 2018;392 (10159): 1789–858. DOI: 10.1016/S0140-6736 (18)32279-7. Epub 2018 Nov 8.
3. Allegri M, Montella S, Salici F et al. Mechanisms of low back pain: a guide for diagnosis and therapy. Version 2. F1000Res. 2016 Jun 28 [revised 2016 Oct 11]; 5; pii: F1000 Faculty Rev-1530. eCollection 2016.
4. Shmagel A, Foley R, Ibrahim H. Epidemiology of Chronic Low Back Pain in US Adults: Data From the 2009–2010 National Health and Nutrition Examination Survey. Arthritis Care Res (Hoboken) 2016; 68 (11): 1688–94. DOI: 10.1002/acr.22890
5. O'Neill TW, McCabe PS, McBeth J. Update on the epidemiology, risk factors and disease outcomes of osteoarthritis. Best Pract Res Clin Rheumatol 2018; 32 (2): 312–26. DOI: 10.1016/j.berh.2018.10.007. Epub 2018 Nov 22.
6. Vos T, Flaxman AD, Naghavi M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859): 2163e96.
7. Cisternas MG, Murphy L, Sacks JJ et al. Alternative methods for defining osteoarthritis and the impact on estimating prevalence in a US population-based survey. Arthritis Care Res 2016; 68 (5): 574e80.
8. http: //www.gks.ru/free_doc/doc_2017/zdrav17.pdf
9. Верткин А.Л., Каратеев А.Е., Кукушкин М.Л. и др. Ведение пациентов с болью в спине для терапевтов и врачей общей практики (клинические рекомендации). Терапия. 2018; 2 (20): 8–18.
[Vertkin A.L., Karateev A.E., Kukushkin M.L. et al. Vedenie patsientov s bol'iu v spine dlia terapevtov i vrachei obshchei praktiki (klinicheskie rekomendatsii). Terapiia. 2018; 2 (20): 8–18 (in Russian).]
10. Qaseem A, Wilt TJ, McLean RM et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med 2017. DOI: 10.7326/M16-2367
11. Bernstein IA, Malik Q, Carville S, Ward S. Low back pain and sciatica: summary of NICE guidance. BMJ 2017; 356: i6748. DOI: 10.1136/bmj.i6748
12. Российские клинические рекомендации. Ревматология. Под ред. Е.Л.Насонова. М.: ГЭОТАР-Медиа, 2017.
[Russian clinical recommendations. Rheumatology. Pod red. E.L.Nasonova. Moscow: GEOTAR-Media, 2017 (in Russian).]
13. Bannuru RR, Osani MC, Vaysbrot EE et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 2019; pii: S1063-4584 (19)31116-1. DOI: 10.1016/j.joca.2019.06.011
14. Bruyère O, Honvo G, Veronese N et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum 2019; pii: S0049-0172 (19)30043-5. DOI: 10.1016/j.semarthrit.2019.04.008
15. http://www.consultant.ru/cons/cgi/online.cgi?req=doc&base=EXP&n=414750# 06438418585438186
16. Chou R, Fu R, Carrino JA, Deyo RA. Imaging strategies for low-back pain: systematic review and meta-analysis. Lancet 2009; 373 (9662): 463–72. DOI: 10.1016/S0140-6736 (09)60172-0
17. Sarzi-Puttini P, Atzeni F, Lanata L et al. Pain and ketoprofen: what is its role in clinical practice? Reumatismo 2010; 62 (3): 172–88.
18. Kokki H. Ketoprofen pharmacokinetics, efficacy, and tolerability in pediatric patients. Paediatr Drugs 2010; 12 (5): 313–29.
19. Díaz-Reval M, Ventura-Martínez R, Déciga-Campos M et al. Evidence for a central mechanism of action of S- (+)-ketoprofen. Eur J Pharmacol 2004; 483 (2–3): 241–8.
20. Gaskell H, Derry S, Wiffen PJ, Moore RA. Single dose oral ketoprofen or dexketoprofen for acute postoperative pain in adults. Cochrane Database Syst Rev 2017; 5: CD007355. DOI: 10.1002/14651858.CD007355.pub3
21. Sarzi-Puttini P, Atzeni F, Lanata L, Bagnasco M. Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis. Clin Exp Rheumatol 2013; 31 (5): 731–8. Epub 2013 May 17.
22. Le Loet X. Safety of ketoprofen in the elderly: a prospective study on 20,000 patients. Scand J Rheumatol (Suppl.) 1989; 83: 21–7.
23. Helin-Salmivaara A, Saarelainen S, Gronroos J et al. Risk of upper gastrointestinal events with the use of various NSAIDs: A case-control study in a general population. Scan J Gastroenterol 2007; 42: 923–32.
24. Чичасова Н.В., Иммаметдинова Г.Р., Каратеев А.Е. и др. Эффективность и безопасность кетопрофена (кетонал) при ревматоидном артрите (клинико-эндоскопическое исследование). Научно-практическая ревматология. 2001; 1: 47–52.
[Chichasova N.V., Immametdinova G.R., Karateev A.E. et al. Effektivnost' i bezopasnost' ketoprofena (ketonal) pri revmatoidnom artrite (kliniko-endoskopicheskoe issledovanie). Nauchno-prakticheskaia revmatologiia. 2001; 1: 47–52 (in Russian).]
25. Осипова Н.А., Петрова В.В., Ермолаев П.М., Береснев В.А. Нестероидные противовоспалительные препараты в лечении послеоперационной боли у онкологических больных. Фарматека, 2006; 6 (121).
[Osipova N.A., Petrova V.V., Ermolaev P.M., Beresnev V.A. Nesteroidnye protivovospalitel'nye preparaty v lechenii posleoperatsionnoi boli u onkologicheskikh bol'nykh. Farmateka, 2006; 6 (121) (in Russian).]
26. Шмидт Е.И., Коган К.М., Белозерова И.В. Оценка эффективности кетонала ретард у больных остеоартрозом. Научно-практическая ревматология. 2000; 2: 77–9.
[Shmidt E.I., Kogan K.M., Belozerova I.V. Otsenka effektivnosti ketonala retard u bol'nykh osteoartrozom. Nauchno-prakticheskaia revmatologiia. 2000; 2: 77–9 (in Russian).]
27. Новиков Г.А., Вайсман М.А., Прохоров Б.М. и др. Кетонал в лечении болевого синдрома у пациентов с распространенными формами злокачественных новообразований. Паллиативная медицина и реабилитация. 2002; 3: 48–51.
[Novikov G.A., Vaisman M.A., Prokhorov B.M. et al. Ketonal v lechenii bolevogo sindroma u patsientov s rasprostranennymi formami zlokachestvennykh novoobrazovanii. Palliativnaia meditsina i reabilitatsiia. 2002; 3: 48–51 (in Russian).]
28. Лазебник Л.Б., Дроздов В.Н., Коломиец Е.В. Сравнительная эффективность и безопасность применения кетопрофена, лорноксикама, нимесулида и целекоксиба у больных остеоартрозом. РМЖ. 2004; 12 (14): 844–7.
[Lazebnik L.B., Drozdov V.N., Kolomiets E.V. Sravnitel'naia effektivnost' i bezopasnost' primeneniia ketoprofena, lornoksikama, nimesulida i tselekoksiba u bol'nykh osteoartrozom. RMZh. 2004; 12 (14): 844–7 (in Russian).]
29. Singh G, Mithal A., Triadafilopoulos G. Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis; selectivity is with patients, not the drug. Ann Rheum Dis 2005; 64 (Suppl. 3): 85.
30. Solomon D, Glynn R, Levin R, Avorn J. Nonsteroidal Anti-inflammatory Drug Use and Acute Myocardial Infarction. Arch Intern Med 2002; 162: 1099–104.
31. Helin-Salmivaara A, Virtanen A, Vesalainen R et al. NSAID use and the risk of hospatalisation for first myocardial infarction in the general population: a national case-control study from Finland. Eur Heart J 2006; 27: 1657–63.
32. Данилов А.Б. Кетонал ДУО в лечении болевого синдрома. Эффективная фармакотерапия. Неврология и психиатрия. 2013; 1: 8–10.
[Danilov A.B. Ketonal DUO v lechenii bolevogo sindroma. Effektivnaia farmakoterapiia. Nevrologiia i psikhiatriia. 2013; 1: 8–10 (in Russian).]
33. Филатова Е.Г. Кетонал: возможности ступенчатой терапии острой боли. Лечение заболеваний нервной системы. 2015; 2.
[Filatova E.G. Ketonal: vozmozhnosti stupenchatoi terapii ostroi boli. Lechenie zabolevanii nervnoi sistemy. 2015; 2 (in Russian).]
34. Чичасова Н.В., Камалова Р.Г., Плаксина Т.В., Попов А.А. Новые аспекты лечения хронической̆ боли: многоцентровое открытое клиническое испытание препарата Кетонал Дуо у больных с дегенеративными заболеваниями суставов. НПР. 2014; 52 (2): 195–201.
[Chichasova N.V., Kamalova R.G., Plaksina T.V., Popov A.A. Novye aspekty lecheniia khronicheskoй̆ boli: mnogotsentrovoe otkrytoe klinicheskoe ispytanie preparata Ketonal Duo u bol'nykh s degenerativnymi zabolevaniiami sustavov. NPR. 2014; 52 (2): 195–201 (in Russian).]
35. https: //www.rlsnet.ru/tn_index_id_41660.htm
36. Matsumoto A, Cavanaugh P. Etoricoxib. Drugs Today (Barc) 2004; 40 (5): 395–414.
37. Martina S, Vesta K, Ripley T. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother 2005; 39 (5): 854–62.
38. Давыдов О.С. Периферические и центральные механизмы перехода острой боли в хроническую и возможная роль ингибирования циклооксигеназы 2 в предотвращении хронизации болевого синдрома. Неврология, нейропсихиатрия, психосоматика. 2016; 8 (2): 10–6.
[Davydov O.S. Perifericheskie i tsentral'nye mekhanizmy perekhoda ostroi boli v khronicheskuiu i vozmozhnaia rol' ingibirovaniia tsiklooksigenazy 2 v predotvrashchenii khronizatsii bolevogo sindroma. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2016; 8 (2): 10–6 (in Russian).]
39. Clarke R, Derry S, Moore R. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev 2012; 4: CD004309.
40. Schumacher H, Boice J, Dahikh D et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002; 324: 1488–92.
41. Da Costa BR, Reichenbach S, Keller N et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 2016; 387 (10033): 2093–105.
42. Jung SY, Jang EJ, Nam SW et al. Comparative effectiveness of oral pharmacologic interventions for knee osteoarthritis: A network meta-analysis. Mod Rheumatol 2018; 28 (6): 1021–8. DOI: 10.1080/14397595.2018.1439694. Epub 2018 Mar 1.
43. Zacher J, Feldman D, Gerli R et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin 2003; 19 (8): 725–36.
44. Reginster J, Malmstrom K, Mehta A et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis 2007; 66 (7): 945–51.
45. Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis. Pain 2016; 157 (8): 1634–44.
46. Moss P, Benson HAE, Will R, Wright A. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage 2017; pii: S1063-4584 (17)31091-9.
47. Ramey D, Watson D, Yu C et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005; 21 (5): 715–22.
48. Watson D, Bolognese J, Yu C et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin 2004; 20 (12): 1899–908.
49. Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. PLoS One 2018; 13 (1): e0190798. DOI: 10.1371/journal.pone.0190798. eCollection 2018.
50. Cannon C, Curtis S, FitzGerald G et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368: 1771–81.
51. Каратеев А.Е. Дестабилизация артериальной гипертензии как осложнение терапии нестероидными противовоспалительными препаратами: значение проблемы. Современная ревматология. 2018; 12 (2): 64–72. https://doi.org/10.14412/1996-7012-2018-2-64-72
[Karateev A.E. Destabilizatsiia arterial'noi gipertenzii kak oslozhnenie terapii nesteroidnymi protivovospalitel'nymi preparatami: znachenie problemy. Sovremennaia revmatologiia. 2018; 12 (2): 64–72. https://doi.org/10.14412/1996-7012-2018-2-64-72 (in Russian).]
[Klinicheskie rekomendatsii Obshcherossiiskoi obshchestvennoi organizatsii Assotsiatsiia travmatologov-ortopedov Rossii "Gonartroz" KR 418, zaregistrirovany 2016 g. https://medi.ru/klinicheskie-rekomendatsii/gonoartroz_13985/ (in Russian).]
53. Федеральный закон от 12.04.2010 № 61-ФЗ «Об обращении лекарственных средств». http://www.consultant.ru/document/cons_doc_LAW_99350/
[Federal'nyi zakon ot 12.04.2010 № 61-FZ "Ob obrashchenii lekarstvennykh sredstv". http://www.consultant.ru/document/cons_doc_LAW_99350/ (in Russian).]
54. Закон РФ от 07.02.1992 № 2300-1 «О защите прав потребителей». http://www.consultant.ru/document/cons_doc_LAW_305/
[Zakon RF ot 07.02.1992 № 2300-1 "O zashchite prav potrebitelei". http://www.consultant.ru/document/cons_doc_LAW_305/ (in Russian).]
________________________________________________
1. Pain. Practical Guide for Doctors. Pod red. N.N.Iakhno, M.L.Kukushkina. Moscow: Izd-vo RAMN, 2012 (in Russian).
2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic anlysis for the Global Burden of Disease Study 2017. Lancet 2018;392 (10159): 1789–858. DOI: 10.1016/S0140-6736 (18)32279-7. Epub 2018 Nov 8.
3. Allegri M, Montella S, Salici F et al. Mechanisms of low back pain: a guide for diagnosis and therapy. Version 2. F1000Res. 2016 Jun 28 [revised 2016 Oct 11]; 5; pii: F1000 Faculty Rev-1530. eCollection 2016.
4. Shmagel A, Foley R, Ibrahim H. Epidemiology of Chronic Low Back Pain in US Adults: Data From the 2009–2010 National Health and Nutrition Examination Survey. Arthritis Care Res (Hoboken) 2016; 68 (11): 1688–94. DOI: 10.1002/acr.22890
5. O'Neill TW, McCabe PS, McBeth J. Update on the epidemiology, risk factors and disease outcomes of osteoarthritis. Best Pract Res Clin Rheumatol 2018; 32 (2): 312–26. DOI: 10.1016/j.berh.2018.10.007. Epub 2018 Nov 22.
6. Vos T, Flaxman AD, Naghavi M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859): 2163e96.
7. Cisternas MG, Murphy L, Sacks JJ et al. Alternative methods for defining osteoarthritis and the impact on estimating prevalence in a US population-based survey. Arthritis Care Res 2016; 68 (5): 574e80.
8. http: //www.gks.ru/free_doc/doc_2017/zdrav17.pdf
9. Vertkin A.L., Karateev A.E., Kukushkin M.L. et al. Vedenie patsientov s bol'iu v spine dlia terapevtov i vrachei obshchei praktiki (klinicheskie rekomendatsii). Terapiia. 2018; 2 (20): 8–18 (in Russian).
10. Qaseem A, Wilt TJ, McLean RM et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med 2017. DOI: 10.7326/M16-2367
11. Bernstein IA, Malik Q, Carville S, Ward S. Low back pain and sciatica: summary of NICE guidance. BMJ 2017; 356: i6748. DOI: 10.1136/bmj.i6748
12. Russian clinical recommendations. Rheumatology. Pod red. E.L.Nasonova. Moscow: GEOTAR-Media, 2017 (in Russian).
13. Bannuru RR, Osani MC, Vaysbrot EE et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 2019; pii: S1063-4584 (19)31116-1. DOI: 10.1016/j.joca.2019.06.011
14. Bruyère O, Honvo G, Veronese N et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum 2019; pii: S0049-0172 (19)30043-5. DOI: 10.1016/j.semarthrit.2019.04.008
15. http://www.consultant.ru/cons/cgi/online.cgi?req=doc&base=EXP&n=414750# 06438418585438186
16. Chou R, Fu R, Carrino JA, Deyo RA. Imaging strategies for low-back pain: systematic review and meta-analysis. Lancet 2009; 373 (9662): 463–72. DOI: 10.1016/S0140-6736 (09)60172-0
17. Sarzi-Puttini P, Atzeni F, Lanata L et al. Pain and ketoprofen: what is its role in clinical practice? Reumatismo 2010; 62 (3): 172–88.
18. Kokki H. Ketoprofen pharmacokinetics, efficacy, and tolerability in pediatric patients. Paediatr Drugs 2010; 12 (5): 313–29.
19. Díaz-Reval M, Ventura-Martínez R, Déciga-Campos M et al. Evidence for a central mechanism of action of S- (+)-ketoprofen. Eur J Pharmacol 2004; 483 (2–3): 241–8.
20. Gaskell H, Derry S, Wiffen PJ, Moore RA. Single dose oral ketoprofen or dexketoprofen for acute postoperative pain in adults. Cochrane Database Syst Rev 2017; 5: CD007355. DOI: 10.1002/14651858.CD007355.pub3
21. Sarzi-Puttini P, Atzeni F, Lanata L, Bagnasco M. Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis. Clin Exp Rheumatol 2013; 31 (5): 731–8. Epub 2013 May 17.
22. Le Loet X. Safety of ketoprofen in the elderly: a prospective study on 20,000 patients. Scand J Rheumatol (Suppl.) 1989; 83: 21–7.
23. Helin-Salmivaara A, Saarelainen S, Gronroos J et al. Risk of upper gastrointestinal events with the use of various NSAIDs: A case-control study in a general population. Scan J Gastroenterol 2007; 42: 923–32.
24. Chichasova N.V., Immametdinova G.R., Karateev A.E. et al. Effektivnost' i bezopasnost' ketoprofena (ketonal) pri revmatoidnom artrite (kliniko-endoskopicheskoe issledovanie). Nauchno-prakticheskaia revmatologiia. 2001; 1: 47–52 (in Russian).
25.Osipova N.A., Petrova V.V., Ermolaev P.M., Beresnev V.A. Nesteroidnye protivovospalitel'nye preparaty v lechenii posleoperatsionnoi boli u onkologicheskikh bol'nykh. Farmateka, 2006; 6 (121) (in Russian).
26. Shmidt E.I., Kogan K.M., Belozerova I.V. Otsenka effektivnosti ketonala retard u bol'nykh osteoartrozom. Nauchno-prakticheskaia revmatologiia. 2000; 2: 77–9 (in Russian).
27. Novikov G.A., Vaisman M.A., Prokhorov B.M. et al. Ketonal v lechenii bolevogo sindroma u patsientov s rasprostranennymi formami zlokachestvennykh novoobrazovanii. Palliativnaia meditsina i reabilitatsiia. 2002; 3: 48–51 (in Russian).
28. Lazebnik L.B., Drozdov V.N., Kolomiets E.V. Sravnitel'naia effektivnost' i bezopasnost' primeneniia ketoprofena, lornoksikama, nimesulida i tselekoksiba u bol'nykh osteoartrozom. RMZh. 2004; 12 (14): 844–7 (in Russian).
29. Singh G, Mithal A., Triadafilopoulos G. Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis; selectivity is with patients, not the drug. Ann Rheum Dis 2005; 64 (Suppl. 3): 85.
30. Solomon D, Glynn R, Levin R, Avorn J. Nonsteroidal Anti-inflammatory Drug Use and Acute Myocardial Infarction. Arch Intern Med 2002; 162: 1099–104.
31. Helin-Salmivaara A, Virtanen A, Vesalainen R et al. NSAID use and the risk of hospatalisation for first myocardial infarction in the general population: a national case-control study from Finland. Eur Heart J 2006; 27: 1657–63.
32. Danilov A.B. Ketonal DUO v lechenii bolevogo sindroma. Effektivnaia farmakoterapiia. Nevrologiia i psikhiatriia. 2013; 1: 8–10 (in Russian).
33. Filatova E.G. Ketonal: vozmozhnosti stupenchatoi terapii ostroi boli. Lechenie zabolevanii nervnoi sistemy. 2015; 2 (in Russian).
34. Chichasova N.V., Kamalova R.G., Plaksina T.V., Popov A.A. Novye aspekty lecheniia khronicheskoй̆ boli: mnogotsentrovoe otkrytoe klinicheskoe ispytanie preparata Ketonal Duo u bol'nykh s degenerativnymi zabolevaniiami sustavov. NPR. 2014; 52 (2): 195–201 (in Russian).
35. https: //www.rlsnet.ru/tn_index_id_41660.htm
36. Matsumoto A, Cavanaugh P. Etoricoxib. Drugs Today (Barc) 2004; 40 (5): 395–414.
37. Martina S, Vesta K, Ripley T. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother 2005; 39 (5): 854–62.
38. Davydov O.S. Perifericheskie i tsentral'nye mekhanizmy perekhoda ostroi boli v khronicheskuiu i vozmozhnaia rol' ingibirovaniia tsiklooksigenazy 2 v predotvrashchenii khronizatsii bolevogo sindroma. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2016; 8 (2): 10–6 (in Russian).
39. Clarke R, Derry S, Moore R. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev 2012; 4: CD004309.
40. Schumacher H, Boice J, Dahikh D et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002; 324: 1488–92.
41. Da Costa BR, Reichenbach S, Keller N et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 2016; 387 (10033): 2093–105.
42. Jung SY, Jang EJ, Nam SW et al. Comparative effectiveness of oral pharmacologic interventions for knee osteoarthritis: A network meta-analysis. Mod Rheumatol 2018; 28 (6): 1021–8. DOI: 10.1080/14397595.2018.1439694. Epub 2018 Mar 1.
43. Zacher J, Feldman D, Gerli R et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin 2003; 19 (8): 725–36.
44. Reginster J, Malmstrom K, Mehta A et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis 2007; 66 (7): 945–51.
45. Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis. Pain 2016; 157 (8): 1634–44.
46. Moss P, Benson HAE, Will R, Wright A. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage 2017; pii: S1063-4584 (17)31091-9.
47. Ramey D, Watson D, Yu C et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005; 21 (5): 715–22.
48. Watson D, Bolognese J, Yu C et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin 2004; 20 (12): 1899–908.
49. Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. PLoS One 2018; 13 (1): e0190798. DOI: 10.1371/journal.pone.0190798. eCollection 2018.
50. Cannon C, Curtis S, FitzGerald G et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368: 1771–81.
51. Karateev A.E. Destabilizatsiia arterial'noi gipertenzii kak oslozhnenie terapii nesteroidnymi protivovospalitel'nymi preparatami: znachenie problemy. Sovremennaia revmatologiia. 2018; 12 (2): 64–72. https://doi.org/10.14412/1996-7012-2018-2-64-72 (in Russian).
52. Klinicheskie rekomendatsii Obshcherossiiskoi obshchestvennoi organizatsii Assotsiatsiia travmatologov-ortopedov Rossii "Gonartroz" KR 418, zaregistrirovany 2016 g. https://medi.ru/klinicheskie-rekomendatsii/gonoartroz_13985/ (in Russian).
53. Federal'nyi zakon ot 12.04.2010 № 61-FZ "Ob obrashchenii lekarstvennykh sredstv". http://www.consultant.ru/document/cons_doc_LAW_99350/ (in Russian).
54. Zakon RF ot 07.02.1992 № 2300-1 "O zashchite prav potrebitelei". http://www.consultant.ru/document/cons_doc_LAW_305/ (in Russian).
Авторы
А.Е. Каратеев*1, Д.С. Зубков2
1 ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия;
2 РОО «Ассоциация травматологов-ортопедов Москвы», Москва, Россия
*aekarat@yandex.ru
1 ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия;
2 РОО «Ассоциация травматологов-ортопедов Москвы», Москва, Россия
*aekarat@yandex.ru
________________________________________________
Andrei E. Karateev*1, Dmitrii S. Zubkov2
1 Nasonova Research Institute of Rheumatology, Moscow, Russia;
2 Association of Orthopedic Traumatologists of Moscow, Moscow, Russia
*aekarat@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.